PortfoliosLab logoPortfoliosLab logo
PALI vs. MCRB
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PALI vs. MCRB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Palisade Bio, Inc. (PALI) and Seres Therapeutics, Inc. (MCRB). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PALI achieves a -19.36% return, which is significantly higher than MCRB's -67.54% return. Over the past 10 years, PALI has underperformed MCRB with an annualized return of -69.33%, while MCRB has yielded a comparatively higher -30.79% annualized return.


PALI

1D
-3.32%
1M
-9.76%
6M
27.18%
YTD
-19.36%
1Y
87.62%
3Y*
-60.94%
5Y*
-75.61%
10Y*
-69.33%
ALL TIME*
-49.91%

MCRB

1D
1.05%
1M
-37.60%
6M
-67.63%
YTD
-67.54%
1Y
-65.48%
3Y*
-63.16%
5Y*
-49.15%
10Y*
-30.79%
ALL TIME*
-34.94%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$248.61K$577.47K$564.10K
$4.73M$5.83M$6.50M

PALI vs. MCRB - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PALI
Palisade Bio, Inc.
-19.36%42.42%-81.36%-88.65%-92.00%-75.38%-11.11%-84.19%-81.80%-51.61%
MCRB
Seres Therapeutics, Inc.
-67.54%-10.47%-40.64%-75.00%-32.77%-66.00%610.14%-23.67%-55.42%2.42%

Correlation

The correlation between PALI and MCRB is 0.24, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.24

Correlation (3Y)
Balances recent behavior with more history.

0.17

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.19

Correlation (10Y)
Provides a long-term view across more market conditions.

0.16

Correlation (All Time)
Calculated using the full available price history since Jun 26, 2015

0.17

Fundamentals

Market Cap

PALI:

$328.93M

MCRB:

$46.77M

EPS

PALI:

-$0.27

MCRB:

-$5.17

PB Ratio

PALI:

3.12

MCRB:

1.75

Total Revenue (TTM)

PALI:

$0.00

MCRB:

$1.15M

Gross Profit (TTM)

PALI:

$0.00

MCRB:

$183.00K

EBITDA (TTM)

PALI:

-$26.58M

MCRB:

-$47.68M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Palisade Bio, Inc.

Seres Therapeutics, Inc.

Return for Risk

PALI vs. MCRB — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

PALI
PALI Risk / Return Rank: 7474
Overall Rank
PALI Sharpe Ratio Rank: 6969
Sharpe Ratio Rank
PALI Sortino Ratio Rank: 7979
Sortino Ratio Rank
PALI Omega Ratio Rank: 7373
Omega Ratio Rank
PALI Calmar Ratio Rank: 7777
Calmar Ratio Rank
PALI Martin Ratio Rank: 7272
Martin Ratio Rank

MCRB
MCRB Risk / Return Rank: 1414
Overall Rank
MCRB Sharpe Ratio Rank: 1313
Sharpe Ratio Rank
MCRB Sortino Ratio Rank: 1515
Sortino Ratio Rank
MCRB Omega Ratio Rank: 1414
Omega Ratio Rank
MCRB Calmar Ratio Rank: 1313
Calmar Ratio Rank
MCRB Martin Ratio Rank: 1515
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

PALI vs. MCRB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Palisade Bio, Inc. (PALI) and Seres Therapeutics, Inc. (MCRB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PALIMCRBDifference
Sharpe ratioReturn per unit of total volatility

+1.45

Sortino ratioReturn per unit of downside risk

+2.77

Omega ratioGain probability vs. loss probability

1.22

0.88

+0.33

Calmar ratioReturn relative to maximum drawdown

1.79

-0.79

+2.58

Martin ratioReturn relative to average drawdown

3.23

-1.19

+4.42

PALI vs. MCRB - Sharpe Ratio Comparison

The current PALI Sharpe Ratio is 0.75, which is higher than the MCRB Sharpe Ratio of -0.70. The chart below compares the historical Sharpe Ratios of PALI and MCRB, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PALI vs. MCRB - Drawdown Comparison

The maximum PALI drawdown since its inception was -100.00%, roughly equal to the maximum MCRB drawdown of -99.55%. Use the drawdown chart below to compare losses from any high point for PALI and MCRB.


Loading charts...

Drawdown Indicators


PALIMCRBDifference

Max Drawdown

Largest peak-to-trough decline

-100.00%

-99.55%

-0.45%

Max Drawdown (1Y)

Largest decline over 1 year

-48.17%

-83.76%

+35.59%

Max Drawdown (3Y)

Largest decline over 3 years

-98.27%

-95.41%

-2.86%

Max Drawdown (5Y)

Largest decline over 5 years

-99.98%

-97.97%

-2.01%

Max Drawdown (10Y)

Largest decline over 10 years

-100.00%

-99.38%

-0.62%

Current Drawdown

Current decline from peak

-100.00%

-99.53%

-0.47%

Average Drawdown

Average peak-to-trough decline

-76.46%

-81.63%

+5.17%

Ulcer Index

Depth and duration of drawdowns from previous peaks

26.64%

55.49%

-28.85%

Volatility

PALI vs. MCRB - Volatility Comparison

The current volatility for Palisade Bio, Inc. (PALI) is 17.14%, while Seres Therapeutics, Inc. (MCRB) has a volatility of 21.35%. This indicates that PALI experiences smaller price fluctuations and is considered to be less risky than MCRB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PALIMCRBDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.14%

21.35%

-4.21%

Volatility (6M)

Calculated over the trailing 6-month period

59.08%

70.96%

-11.88%

Volatility (1Y)

Calculated over the trailing 1-year period

115.38%

94.56%

+20.82%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

145.64%

101.44%

+44.20%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

140.93%

152.71%

-11.78%

Dividends

PALI vs. MCRB - Dividend Comparison

Neither PALI nor MCRB has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

PALI vs. MCRB - Financials Comparison

This section allows you to compare key financial metrics between Palisade Bio, Inc. and Seres Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


PALI and MCRB have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MCRB has higher volatility (21.35%) compared to PALI (17.14%). In terms of maximum drawdown, PALI dropped -100.00% vs MCRB's -99.55%.

PALI currently has the higher Sharpe Ratio (0.75 vs -0.70), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PALI and MCRB

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer